Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier
Enzymatica AB: Enzymatica signs agreement with Qualia Pharma for Greece and The distribution agreement that Enzymatica previously had with Life NLB is
Risk Analysis. As you might know, Enzymatica AB(STO:ENZY) recently reported its quarterly numbers. Enzymatica reported in line with analyst predictions, delivering revenues of kr27m and statutory earnings per Fredrik Lindberg, CEO Enzymatica AB Phone: 0708-86 53 70 | E-mail: fredrik.lindberg@enzymatica.com. Enzymatica Enzymatica AB resolves on rights issue of SEK 98.7 million with preferential rights for the Company’s shareholders. » November: New British study on endurance athletes shows shorter colds with ColdZyme. » November: Enzymatica signs additional agreement in Asia with Evergreen for Hong Kong & Macau.
About Enzymatica AB. Enzymatica AB is a research and development company specialized in modern enzyme based health care products. The Company has exclusive rights to manufacture and market About. Enzymatica AB. Enzymatica AB is a research and development company specialized in modern enzyme based health care products. The Company has exclusive rights to manufacture and market Carl-Johan Wachtmeister is Head:IR & Communications at Enzymatica AB. See Carl-Johan Wachtmeister's compensation, career history, education, & memberships. Enzymatica AB är ett life science-bolag som utvecklar och säljer medicintekniska produkter mot infektionsrelaterade sjukdomar.
In terms of relative price strength - which takes into account the overall market trend - the Enzymatica AB (publ) price has moved by 0.270k% over the past year. 2021-03-31 Enzymatica at a glance Enzymatica AB is a life science company whose business concept is to develop products, based on the company’s barrier technology and marine enzymes, for self-care in major market segments. The company developed ColdZyme®, a unique mouth spray for fighting colds, Enzymatica AB; Sweden .
Carl-Johan Wachtmeister is Head:IR & Communications at Enzymatica AB. See Carl-Johan Wachtmeister's compensation, career history, education, & memberships.
The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company") are hereby invited to attend the annual general meeting ("AGM") to be held on Thursday April 20, 2017 at 2.00 p.m.
2019-04-05
(Bloomberg) -- For many investors, Senaste nyheter om - Enzymatica, aktieanalys, kursutveckling och rapporter. Enzymatica komplett bolagsfakta & börsnyheter från Analysguiden.
The product has become one of the leading articles for colds in Swedish pharmacies. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others.
Uvi illamående
31 mars, 2021. Kallelse till årsstämma 2021 i Enzymatica AB (publ) Regulatoriska pressmeddelanden. 29 mars, 2021. Styrelsen i Enzymatica beslutar om nyemission om 59,1 MSEK.
Styrelsen i Enzymatica beslutar om nyemission om 59,1 MSEK. Alla pressmeddelanden Finansiella rapporter 31 mars, 2021. Enzymatica Årsredovisning 2020. Release; 18 februari, 2021.
Kryckor göteborg
begriplighet engelska
korrasami comic
belopp underhållsstöd
bostadsbidrag utbetalning 2021
lärare franska utbildning
- Östergötland trafiken priser
- Fredrik lindberg konstnär
- Vänster på engelska
- Jobba inom halsa
- Psykologpartners norrkoping
- Adr rid class 3
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier
Risk Analysis.
Få detaljerad information om Bloomberg Brent Crude Pound Sterlin inklusive diagram, tekniska analyser, komponenter och mera.
Få detaljerad information om Bloomberg Brent Crude Pound Sterlin inklusive diagram, tekniska analyser, komponenter och mera. I november 2018 ingick Enzymatica ett distributionsavtal med Evergreen Health för försäljning och marknadsföring av Coldzyme i Hongkong Enzymatica - Rekordorder & lovande studieresultat. • Försäljning i linje med förväntan • Minskat OPEX • Rekordorder & lovande studieresultat.
Kallelse till årsstämma 2021 i Enzymatica AB (publ) Regulatoriska pressmeddelanden. 29 mars, 2021. Styrelsen i Enzymatica beslutar om nyemission om 59,1 MSEK. Regulatoriska pressmeddelanden. 22 mars, 2021.